Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) shares dropped 5.7% on Tuesday . The company traded as low as $12.75 and last traded at $12.74. Approximately 9,702 shares changed hands during trading, a decline of 98% from the average daily volume of 454,145 shares. The stock had previously closed at $13.50.
Analyst Ratings Changes
BCAX has been the topic of a number of research reports. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, HC Wainwright boosted their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Buy” and an average target price of $36.50.
Get Our Latest Research Report on BCAX
Bicara Therapeutics Stock Performance
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Spire Wealth Management bought a new position in shares of Bicara Therapeutics in the fourth quarter worth approximately $31,000. BNP Paribas Financial Markets bought a new position in shares of Bicara Therapeutics in the fourth quarter worth approximately $32,000. Legal & General Group Plc bought a new position in shares of Bicara Therapeutics in the fourth quarter worth approximately $33,000. Summit Investment Advisors Inc. bought a new position in shares of Bicara Therapeutics in the fourth quarter worth approximately $35,000. Finally, Virtus ETF Advisers LLC purchased a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $69,000.
Bicara Therapeutics Company Profile
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Stories
- Five stocks we like better than Bicara Therapeutics
- Investing In Automotive Stocks
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Must-Own Stocks to Build Wealth This Decade
- Short Selling: How to Short a Stock
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.